Detection of P53 mutations in different cancer types is improved by cDNA sequencing

Piaskowski,Sylwester; Zawlik,Izabela; Szybka,Malgorzata; Kulczycka-Wojdala,Dominika; Stoczynska-Fidelus,Ewelina; Bienkowski,Michal; Robak,Tadeusz; Kusinska,Renata; Jesionek-Kupnicka,Dorota; Kordek,Radzislaw; Rieske,Piotr; Liberski,Pawel P.

doi:10.3892/ol_00000125

Detection of P53 mutations in different cancer types is improved by cDNA sequencing

Authors:
- Sylwester Piaskowski
- Izabela Zawlik
- Malgorzata Szybka
- Dominika Kulczycka-Wojdala
- Ewelina Stoczynska-Fidelus
- Michal Bienkowski
- Tadeusz Robak
- Renata Kusinska
- Dorota Jesionek-Kupnicka
- Radzislaw Kordek
- Piotr Rieske
- Pawel P. Liberski
View Affiliations

Affiliations: Department of Molecular Pathology and Neuropathology, Chair of Oncology, Medical University of Lodz, 92-216 Lodz, Poland
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000125
Pages: 717-721

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently published data show discrepancies between P53 cDNA and DNA sequencing results in glioblastoma, colorectal cancer and pleomorphic xanthoastrocytoma. We hypothesized that similar discrepancies are observed in other types of human cancers. Using DNA and cDNA direct sequencing, we analyzed 40 cases of invasive breast duct carcinoma, 23 cases of acute myeloblastic leukaemia, 12 cases of astrocytoma and 40 cases of soft tissue sarcoma for P53 mutations. Additionally, we used real-time quantitative PCR to estimate the normalized relative P53 expression. In the comparative study, the P53 mutation was detected more frequently when using cDNA sequencing than DNA sequencing in all of the cancer types. Furthermore, several samples presented missense P53 mutations, with visible wild-type nucleotide on the DNA sequence. In contrast, elimination of the wild-type allele or selective overproduction of the mutated allele was observed on the cDNA sequence. P53 expression was not significantly different between the cases with or without P53 mutations. These results indicate that cDNA sequencing improves the detection of P53 mutations in these cancers. We suggest that the true incidence of P53 mutations in these cancers is underestimated at the DNA level, and evaluation of the alteration should be carried out using cDNA analysis.

View Figures

View References

1	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
2	Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ and Hainaut P: New approaches to understanding p53 gene tumour mutation spectra. Mutat Res. 31:199–209. 1999. View Article : Google Scholar : PubMed/NCBI
3	Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:705–707. 1989. View Article : Google Scholar : PubMed/NCBI
4	Laurent-Puig P, Béroud C and Soussi T: APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res. 26:269–270. 1998. View Article : Google Scholar : PubMed/NCBI
5	Heim RA, Kam-Morgan LN, Binnie CG, et al: Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet. 4:975–981. 1995. View Article : Google Scholar : PubMed/NCBI
6	Valverde JR, Alonso J, Palacios I and Pestaña A: RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet. 6:532005. View Article : Google Scholar : PubMed/NCBI
7	Elledge RM and Allred DC: The p53 tumour suppressor gene in breast cancer. Breast Cancer Res Treat. 32:39–47. 1994. View Article : Google Scholar : PubMed/NCBI
8	Nakano Y, Naoe T, Kiyoi H, et al: Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukaemia. Eur J Haematol. 65:23–31. 2000. View Article : Google Scholar : PubMed/NCBI
9	Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL and Radich JP: FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukaemia. Blood. 97:3589–3595. 2001. View Article : Google Scholar : PubMed/NCBI
10	Thangnipon W, Mizoguchi M, Kukita Y, Inazuka M, Iwaki T, Fukui M and Hayashi K: Distinct pattern of PCR-SSCP analysis of p53 mutations in human astrocytomas. Cancer Lett. 141:195–201. 1999. View Article : Google Scholar : PubMed/NCBI
11	Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
12	Taubert H, Würl P, Bache M, et al: The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry. Anticancer Res. 18:183–187. 1998.PubMed/NCBI
13	Patterson H, Gill S, Fisher C, et al: Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer. 69:1052–1058. 1994. View Article : Google Scholar : PubMed/NCBI
14	Pharaoh PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 80:1968–1973. 1999. View Article : Google Scholar : PubMed/NCBI
15	Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 88:173–182. 1996.
16	Peraud A, Kreth FW, Wiestler OD, Kleihues P and Reulen HJ: Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. 8:1117–1124. 2002.PubMed/NCBI
17	Taubert H, Meye A and Würl P: Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 56:4134–4136. 1996.PubMed/NCBI
18	Williams C, Norberg T, Ahmadian A, et al: Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem. 44:455–462. 1998.PubMed/NCBI
19	Forslund A, Kressner U, Lönnroth C, Andersson M, Lindmark G and Lundholm K: P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. Int J Oncol. 21:409–415. 2002.PubMed/NCBI
20	Szybka M, Zawlik I, Kulczycka D, et al: Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53. Br J Cancer. 98:1431–1433. 2008. View Article : Google Scholar : PubMed/NCBI
21	Szybka M, Zakrzewska M, Rieske P, et al: cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer. 11:2782009. View Article : Google Scholar : PubMed/NCBI
22	Zakrzewska M, Szybka M, Biernat W, Papierz T, Rieske P, Liberski PP and Zakrzewski K: Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry. Cancer Genet Cytogenet. 193:93–97. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zakrzewska M, Wojcik I, Zakrzewski K, et al: Mutational analysis of hSNF5/INI1 and P53 genes in choro id plexus carcinomas. Cancer Genet Cytogenet. 156:179–182. 2005. View Article : Google Scholar : PubMed/NCBI
24	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
25	Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T and Bartkowiak J: Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma. 52:318–324. 2005.PubMed/NCBI
26	Rieske P, Bartkowiak JK, Szadowska AM, Olborski B, Harezga-Bal B and Debiec-Rychter M: A comparative study of P53/MDM2 gene alterations and P53/MDM2 protein immunoreactivity in soft-tissue sarcomas. J Exp Clin Cancer Res. 18:403–416. 1999.PubMed/NCBI
27	Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyö EM and Uhlén M: Analysis of heterogenous viral populations by direct DNA sequencing. Bio Techniques. 15:120–126. 1993.PubMed/NCBI
28	Singer G, Stöhr R, Cope L, et al: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 29:218–224. 2005. View Article : Google Scholar